Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sun Pharma Managing Director Dilip Shanghvi On Building Its U.S. Base: An Interview With PharmAsia News (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

With a robust business strategy of strengthening its U.S. operations, India's Sun Pharmaceutical has emerged as the most valued Indian drug company. As stock markets hammered down valuations for other top Indian drug companies like Ranbaxy, Dr. Reddy's and Cipla, analysts have largely held Sun's valuations steady. In a rare interview with PharmAsia News' Indian bureau, Sun Pharmaceutical Chairman and Managing Director Dilip Shanghvi shares his thoughts on the long term goals for the company and speaks out on the tangle that his company is engaged in to acquire Israeli drug maker Taro.
Advertisement

Related Content

Sun Pharma Managing Director Dilip Shanghvi On Building A U.S. Base: An Interview With PharmAsia News (Part 1 of 2)
Sun Pharma Managing Director Dilip Shanghvi On Building A U.S. Base: An Interview With PharmAsia News (Part 1 of 2)
Daiichi/Lilly’s Prasugrel Overcomes Cancer Hurdle, Receives Favorable Panel Recommendation
Advertisement
UsernamePublicRestriction

Register

SC070895

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel